BOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as Chair




BOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as Chair

• Seasoned life science investor, executive and board leader to support next phase of growth as BOOST Pharma advances BT-101, a promising and potentially disease-modifying therapy for osteogenesis imperfecta

STOCKHOLM, March 19, 2026 (GLOBE NEWSWIRE) — BOOST Pharma (“BOOST” or the “Company), a clinical‑stage biopharmaceutical company developing novel, first‑in‑class off-the-shelf cell therapies for rare, debilitating pediatric skeletal diseases, today announced the appointment of highly respected industry leader Elaine Jones, PhD, as Chair of its Board of Directors. Elaine succeeds Ingelise Saunders, who will remain on the Board.

Elaine Jones is a distinguished biopharmaceutical executive, venture investor, and board leader, bringing more than two decades of experience shaping and scaling innovative life science companies. Over her career, she has served on more than 35 company boards and held senior roles across the global biotechnology ecosystem, including as Vice President of Venture Capital at Pfizer Ventures, where she oversaw strategic investments in companies aligned with Pfizer’s R&D priorities, and earlier in leadership roles at GSK’s corporate venture fund, SR One.

Her appointment marks an important inflection point for BOOST Pharma as it advances BT-101, its lead off-the-shelf cell therapy for osteogenesis imperfecta (OI), also known as Brittle Bone Disease, toward Phase III clinical development. BT-101 has shown promising data in early clinical trials demonstrating reductions in fractures among affected children, supporting its potential as the first disease-modifying therapy for this severe rare condition.

Hans Schambye, Chief Executive Officer of BOOST Pharma, said: “Elaine’s unique combination of strategic insight, investment acumen and deep board leadership experience will be invaluable as we prepare BT‑101 for late‑stage development and drive the Company into its next phase of growth. I would also like to express my sincere thanks to Ingelise Saunders for her outstanding service as Chair. She has guided BOOST through critical milestones and challenging periods with exceptional commitment, and we are delighted she will continue contributing as a Board Director.”

Elaine currently serves on the boards of CytomX Therapeutics, HBM Healthcare Investments AG, and NextCure, is Chair of Mironid, and is also a member of the Board of the Novartis Venture Fund.

Dr. Elaine Jones, incoming Chair of BOOST Pharma, commented: “BOOST Pharma has the scientific vision, clinical ambition, and highly experienced team to position the company for long-term success. BT‑101 is an especially compelling program, with the potential to meaningfully improve the lives of children living with osteogenesis imperfecta. I look forward to supporting BOOST as it advances this promising therapy into late‑stage development and builds further value for patients, partners, and investors.”

As BOOST Pharma enters this next stage of growth, the Company will meet with partners and investors at key industry events this spring, including BIO-Europe Spring and LSX World Congress Europe, where CEO Hans Schambye will participate in expert panel discussions.

For more information, please contact:

Optimum Strategic Communications
Zoe Bolt | Vareen Outhonesack | Nellie Stephens

Tel: +44 (0) 20 388 296 21

Email: boostpharma@optimumcomms.com

About BOOST Pharma

BOOST Pharma ApS is a clinical‑stage biotechnology company developing novel, first‑in‑class off-the-shelf stem cell therapies for rare, debilitating pediatric skeletal diseases. The Company’s lead program, BT‑101, is an allogeneic mesenchymal stem cell therapy for osteogenesis imperfecta, a severe rare bone disorder, and has received Orphan Drug Designation in both the U.S. and Europe. BT‑101 is currently advancing toward a planned Phase III clinical trial.

BOOST is backed by a strong syndicate of life‑science investors, including Industrifonden, Karolinska Development, and Sound Bioventures, who support the Company’s strategy focused on high‑impact science, capital‑efficient development, and clear pathways to market. The Company is led by a team with deep experience in biotech innovation, clinical execution, and value creation. For further information, please visit https://boostpharma.com/.

About Osteogenesis Imperfecta

Osteogenesis Imperfecta (OI), also known as Brittle Bone Disease, is a rare and devastating genetic disorder characterized by extremely fragile bones, reduced bone mass, and frequent fractures, often beginning in infancy. Individuals with OI may experience dozens to hundreds of fractures over a lifetime, along with loose joints, weakened teeth, and significant skeletal deformities. Beyond bone fragility, people living with OI frequently face muscle weakness, fatigue, curved bones, scoliosis, respiratory complications, early‑onset hearing loss, and short stature, all contributing to substantial impacts on overall health and quality of life.

There are currently no FDA or EMA‑approved disease‑modifying therapies for OI; existing management is purely supportive, aimed at reducing fracture risk and preserving mobility. OI affects an estimated 1 in 15,000 people globally, underscoring the urgent need for safe and effective treatments.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8d6a4ee5-196c-4500-b705-394f7e47eec1

SK pharmteco Reaffirms Three-Business-Unit Strategy, Strengthens Global Gene Therapy Business Unit with Funding Commitment




SK pharmteco Reaffirms Three-Business-Unit Strategy, Strengthens Global Gene Therapy Business Unit with Funding Commitment

RANCHO CORDOVA, Calif., March 19, 2026 (GLOBE NEWSWIRE) — SK pharmteco today announced a significant funding commitment to support strategic initiatives within its viral vector business, while reaffirming its long-term growth strategy across three business units: small molecule, peptides, and viral vectors.

SK pharmteco is sharpening its strategy to provide pharmaceutical and biotechnology partners with the financial strength, technical rigor, and operational infrastructure needed for long-term success across multiple modalities. The company continues to expand its small molecule and peptide businesses while reinforcing its commitment to viral vector development and manufacturing, and believes this three-business-unit approach positions SK pharmteco as a versatile CDMO partner for biopharma companies managing increasingly diverse pipelines, from established therapeutics to advanced therapies.

To advance this strategy, $100 million USD will be deployed to reinforce and expand capabilities across the company’s viral vector business, including its centers of excellence in King of Prussia, Pennsylvania, and Corbeil-Essonnes, France. SK pharmteco is prioritizing operational excellence with a focus on further maturing quality systems, optimizing process performance, and advancing technology transfer while enabling innovation across its global network to deliver more reliable development, late-stage, and commercial execution.

“Our strategy is built on the strength of three essential business units: small molecules, peptides, and viral vectors,” said Joerg Ahlgrimm, Chief Executive Officer of SK pharmteco. “As the industry evolves, our partners need a CDMO that combines specialized expertise, technical sophistication, and operational reliability across modalities. This commitment supports our continued efforts to strengthen our viral vector business while advancing the broader capabilities, quality, and commercial readiness that customers expect across our global network.”

By advancing its three-business-unit strategy, SK pharmteco is strengthening its position as a differentiated global CDMO, combining the reliability and scale of established small molecule manufacturing, the specialized capabilities of its peptides business, and the advanced expertise required to support the development and manufacture of viral vector-based therapies.

About SK pharmteco
SK pharmteco is a global contract development and manufacturing organization (CDMO) with production sites, research & development facilities, and analytical laboratories across the U.S., Europe, and South Korea. The company’s core capabilities center on small molecules, peptides, and viral vectors, providing the specialized expertise needed to bring complex therapies to market. Through these pillars, SK pharmteco supports biopharmaceutical partners of all sizes with comprehensive development and manufacturing solutions worldwide. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea’s second-largest conglomerate.

Contact:
Keith Bowermaster, APR, CCMP
Communications Consultant
keith.bowermaster@skpt.com

Persica Pharmaceutical’s PP353 Phase 1b Data Selected for Oral Presentation at the American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting




Persica Pharmaceutical’s PP353 Phase 1b Data Selected for Oral Presentation at the American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting

ASIPP presentation follows publication of positive data from PP353 Phase 1b Modic Trial in The Lancet’s eClinicalMedicine

London, UK, 19 March 2026 – Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative treatment for chronic Low Back Pain (cLBP), today announces that it has been selected to give an oral presentation at the American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting, taking place from 19 March to 21 March, in New Orleans, USA.

Dr. Joshua Hirsch, Neurointerventionalist, Professor at Harvard Medical School, Board Member of ASIPP and medical advisor to Persica will be presenting PP353 data from the Company’s Phase 1b Modic Trial published in The Lancet’s eClinicalMedicine in February 2026. The data show that PP353 – Persica’s targeted, non-opioid therapeutic approach – demonstrated clinically meaningful and statistically significant improvements in pain and disability in patients with cLBP and Modic type 1 changes.

The company will also present an e-poster which will be on display throughout the meeting and published in an upcoming issue of the Pain Physician journal.

Duncan McHale, Chief Medical Officer of Persica Pharmaceuticals, said: “ASIPP is a leading meeting for companies working in pain, and we’re proud that Persica’s abstract ranked in the top five and was selected for an oral presentation this year – an additional strong validation of our science. PP353 is an innovative approach that targets the underlying disease of chronic Low Back Pain rather than just the symptoms. We’re excited to share the progress we’re making towards our goal of delivering a novel treatment option for the millions suffering with this debilitating condition that causes severe disability, as well as putting a significant burden on healthcare systems.”

Dr. Joshua Hirsch, Neurointerventionalist, Professor at Harvard Medical School and Board Member of ASIPP, added: “Chronic low back pain remains difficult to treat and places a substantial burden on patients and healthcare systems worldwide. Many patients cycle through existing therapies with limited relief, underscoring the urgent need for new treatment approaches. A targeted, non-opioid therapy like PP353, that addresses the underlying cause of disease, has the potential to meaningfully improve how we treat this large patient population and I look forward to seeing PP353 advance into Phase 3 studies.”

Presentation details:

To read the full paper: Intradiscal linezolid (PP353) treatment for chronic low back pain associated with Modic change type 1: an international, first-in-human, randomised, sham procedure-controlled, double-blind, phase 1b clinical trial

For further information:        
ICR Healthcare – Tracy Cheung, Chris Welsh, Emily Johnson        
persica@icrhealthcare.com

About Persica Pharmaceuticals        
Persica Pharmaceuticals is a clinical-stage biotechnology company developing PP353, a groundbreaking and transformative treatment for chronic Low Back Pain (cLBP) with Modic type 1 changes. Modic changes are a sign of inflammation, visible on Magnetic Resonance Imaging (MRI) scans at the vertebral endplate adjacent to a degenerate lumbar disc, and which can extend into the body of the vertebrae. PP353 is a patented, targeted intradiscal antibiotic injection that is delivered directly to the site of infection. It is a non-opioid treatment which addresses an underlying cause of cLBP, rather than just the symptoms, and removes the need for extended duration of antibiotic treatment.

About PP353        
PP353 (intradiscal linezolid) is a suspension of linezolid powder in a thermosensitive vehicle, which is liquid at room temperature but increases in viscosity when injected into the site of infection and warmed to body temperature. This increase in viscosity prevents PP353 from leaking out of the degenerate disc into adjacent tissues during injection. PP353 also contains a radio-opaque dye, which allows the physician to use image guidance to make sure the gel is positioned correctly in the target disc on injection.

About chronic Low Back Pain with Modic Type 1 changes        
Chronic Low Back Pain (> 6 months) with Modic Type 1 changes is a common patient subgroup. These patients are readily identifiable on MRI and typically suffer from moderate to severe persistent pain and disability with limited relief from the current standard of care – physiotherapy and analgesia including opioids – with a prevalence of four million patients in the US, EU and Japan. Current treatment options provide only limited short-term relief or involve invasive, irreversible nerve ablation, which does not address the underlying cause of pathology, i.e., a suspected disc infection.

Roquette’s 2025 results show the resilience of its expanded portfolio in a very difficult market environment




Roquette’s 2025 results show the resilience of its expanded portfolio in a very difficult market environment

Roquette’s 2025 results show the resilience of its expanded portfolio in a very difficult market environment

The Group’s strategy and recent acquisitions enable upselling to higher-value markets

• +8% turnover growth to €4.9 billion (-5% Like-For-Like basis, LFL¹) and +13% Current EBITDA increase to €612 million, driven by the pharmaceutical and food specialties businesses.
• +54 bps increase in Current EBITDA margin to 12.6% showing the value of recent strategic acquisitions and the resulting evolution of the Group’s portfolio.
• Excluding the cash impact of the IFF Pharma Solutions acquisition, Free Cash-Flow landed at €301 million.
• In 2025, Roquette maintained a robust balance sheet with a strong liquidity position and a net debt to combined Current EBITDA ratio of 3.48x versus 3.72x end of June.
• Early 2026, Roquette launched ‘Shift & Lead’, a comprehensive company plan to reinforce its competitiveness, strengthen its market position, and provide long-term value creation to all stakeholders.

Lille – March 19^th, 2026 – Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, today announced its 2025 full-year results, following the approval of its financial statements by the Board of Directors.

Thierry Fournier, CEO of Roquette, commented on the period: “We are seeing the significant benefits of our recent strategic moves and acquisitions, which allow Roquette to offer a more comprehensive portfolio and reinforce our focus on high-value products and markets. Despite a very challenging environment characterized by soft demand, overcapacity, and persistent geopolitical and economic uncertainties, our specialty products remain the key driver of our resilient performance in 2025.”

Regarding the Health & Pharma Solutions Business Unit, the strong performance from new product lines coming from the recent IFF Pharma Solutions acquisition mitigated the effect of softer demand and destocking in the starch and capsules markets, with notable gains from cellulose and alginates products for oral dosage. 

The Nutrition & Bioindustry Business Unit delivered strong results in food specialties, even in the face of sluggish markets and intense competition, with higher demand in food and nutrition, particularly for fiber and protein products. Combined with increased unit prices and lower variable costs, this has resulted in significant margin improvements for specialty products.

Collectively, these achievements strengthened Roquette’s market position and delivered resilient results in a complex landscape, affirming how the company’s strong foundations allow it to continue growing in a volatile and highly competitive environment. “Throughout 2026, we will maintain our commitment to operational excellence, innovation, financial discipline, and cash generation. Guided by our purpose: “Together, we turn the potential of nature into the essentials of life”, we are determined to become the global leader in sustainable plant-based solutions, driven by outstanding innovation and strong client partnerships that shape the future of nutrition, health and bioindustry. By defining and executing ‘Shift & Lead’, our comprehensive company plan, we will reinforce our competitiveness, strengthen our market position, and build for long-term value creation for all our stakeholders”, concluded Thierry Fournier.

FULL YEAR 2025 CONSOLIDATED KEY FIGURES²

^{(a) Excluding non-recurring items amounting to €335 million (€44 million in FY 24), associated taxes and one-off deferred tax charges in the USA.
(b) IFF Pharma Solutions acquired on May 1st, 2025
(c) Combined Current EBITDA includes IFF Pharma Solutions estimated Current EBITDA over the last twelve months.}

FINANCIAL PERFORMANCE

EXPANDED PORTFOLIO DRIVES PERFORMANCE IN A HIGHLY CHALLENGING ENVIRONMENT

In 2025, Roquette operated in a particularly demanding environment marked by soft global demand, overcapacity in certain commodity markets, intensified competition, and continued geopolitical and macroeconomic uncertainties. Against this backdrop, the Group delivered resilient full-year results, demonstrating the relevance of its strategic repositioning toward higher-value markets and products.

Full-year turnover reached €4,877 million, up 8% compared to 2024, given the integration of IFF Pharma Solutions from May 1st, 2025. On a Like-for-Like basis, sales were down 5%, reflecting continued pressure in commodity markets and softer demand in selected pharmaceutical segments.

Current EBITDA increased by +13% to €612 million, representing a margin of 12.6%, up +54 basis points compared to 2024. On a Like-for-Like basis, Current EBITDA was down -14% (margin down -115 basis points), reflecting competitive pressures, partially offset by disciplined cost management and a favorable product mix. Margin improvement was primarily driven by the contribution of IFF Pharma Solutions, consolidated since May 1st, 2025, strong performance in food specialties, continued execution of the Group’s competitiveness program and a favorable cost environment compared to the peak inflationary period of 2022–2023.

Reported net loss for 2025 amounted to €265 million, mainly reflecting the impact of non-recurring items, including the acquisition and integration costs related to IFF Pharma Solutions (€87 million) and impairment charges (€231 million). Excluding non-recurring items and associated taxes, adjusted net result stood at €70 million.

FREE CASH-FLOW GENERATION

Excluding the impact of the IFF Pharma Solutions acquisition, the Group generated positive free cash-flow of €301 million in 2025, supported in particular by solid operating cash-flow and a positive contribution from working capital requirement (WCR).

WCR remained broadly stable at 19.0% of sales in 2025, compared with 18.9% at year-end 2024. This evolution reflects higher sales following the integration of IFF Pharma Solutions and, to a lesser extent, higher inventory levels, which were contained thanks to proactive and efficient inventory management initiatives.

The Group maintained a strong focus on WCR management throughout the year, including the use of receivables factoring at year-end, which contributed approximately €128 million to free cash-flow generation in 2025. This measure helped to preserve financial flexibility and support the Group’s investment capacity.

Total investments amounted to €263 million in 2025, compared with €234 million in 2024, reflecting the Group’s continued commitment to innovation, industrial excellence and capacity expansion in higher-value segments, thereby supporting its long-term profitable growth potential.

PERFORMANCE BY BUSINESS UNIT

HEALTH & PHARMA SOLUTIONS – STRONG PERFORMANCE FROM NEW PRODUCT LINES MITIGATES MARKET PRESSURE

The full-year performance of the Health & Pharma Solutions Business Unit was primarily driven by the integration of IFF Pharma Solutions, which generated a positive perimeter effect, and by strong momentum across specialty excipient technologies, including cellulose, alginates and polymers. Polyox achieved record sales over the year, reflecting sustained demand in high-value applications.

The enlarged portfolio has significantly strengthened Roquette’s position as a global drug delivery partner, offering a comprehensive range of excipient technologies including starch, cellulose, alginates, and capsules, while further rebalancing the Group’s mix toward higher-value markets and products.

However, the business operated in a complex market environment marked by soft demand and destocking in the capsules segment, intense competition on polyols from Chinese players, particularly in Europe, and pricing pressure in selected product categories. Lower volumes in capsules were partially offset by variable cost improvement.

Despite these headwinds, the contribution of IFF Pharma Solutions and the resilience of high-value excipient technologies supported overall commercial and operating performance. The IFF Pharma Solutions acquisition nurtured profitability, confirming its strong strategic relevance and placing Roquette on a sustained value creation trajectory.

NUTRITION & BIOINDUSTRY – SPECIALTIES HOLDING UP AS COMMODITIES REACH CYCLICAL LOW

The Nutrition & Bioindustry Business Unit demonstrated resilience with strong performance in food specialties despite a particularly challenging market environment.

Commodity demand for starch and starch derivatives reached historically low levels in late 2025, reflecting structural overcapacity and subdued market conditions. Against this backdrop, Roquette continued to gain market share in starch and starch derivatives, particularly in Europe, while facing strong price pressure in Europe linked to the decline in sugar prices and intense competition in India.

The Food & Nutrition segment delivered strong performance, benefiting from higher demand across specialty applications, including proteins and fibers, especially in Europe, as well as increased unit prices and lower variable costs. As a result, specialty products delivered significant margin improvement within the Business Unit, partially offsetting persistent pressure in commodity segments.

BALANCE SHEET

^{(a) Non-audited H1 25 consolidated accounts
(b) Combined Current EBITDA includes IFF Pharma Solutions estimated EBITDA over the last twelve months.}

Acquisition-driven leverage, commitment to maintaining a strong investment-grade credit profile

Net financial debt amounted to €2,390 million at year-end 2025, compared with €2,854 million at half-year 2025. This decrease reflects the intra-year seasonality of working capital requirement and strong free cash-flow generation. The restated leverage ratio (Net debt IFRS / Combined Current EBITDA) improved to 3.48x, compared to 3.72x at the end of June 2025, demonstrating the initial effects of the IFF Pharma Solutions acquisition and disciplined financial management in the second half of the year.

Roquette has defined a clear deleveraging trajectory and targets a return to a leverage ratio between 2.3x and 2.7x by 2027, consistent with its commitment to maintaining a strong investment-grade credit profile (target BBB). Under the “Shift & Lead” strategic plan, the Group is committed to disciplined capital allocation and enhanced cash generation. The plan focuses on operational excellence and margin expansion, supporting a structural improvement in free cash-flow generation and progressive deleveraging.

Successful post-acquisition refinancing

The bridge financing put in place to fund the acquisition of IFF Pharma Solutions has been fully refinanced through the issue by the Group of two US Private Placements (USPP). In November 2025, Roquette issued a USD 450 million USPP with maturities ranging from 2032 to 2040. In December 2025, a second €200 million USPP was issued, with maturities ranging from 2032 to 2037. These transactions further diversified the Group’s investor base and funding sources across EUR and USD markets, while significantly extending its debt maturity profile.

The acquisition of IFF Pharma Solutions has been financed through a diversified and balanced combination of instruments, including:

• A €0.6 billion hybrid Eurobond (accounted for 100% as equity under IFRS);
• A €0.6 billion senior Eurobond, maturing in 2031;
• Approximately €0.6 billion equivalent in EUR and USD US Private Placements (USPP), ultimately maturing in 2040;
• Approximately €0.6 billion equivalent in EUR and USD amortizing term loans, maturing in 2029.

This successful refinancing demonstrates the Group’s continued access to capital markets following the acquisition and reflects investors’ confidence in Roquette’s credit fundamentals and long-term strategy.

Strong liquidity and balanced maturity profile

As of December 31^st, 2025, gross financial debt amounted to €3.2 billion. The Group benefits from a well-balanced and staggered maturity profile, with an average debt maturity of 6.1 years and no material refinancing concentration in the short term. Available liquidity totaled €1,558 million at year-end, including €763 million of undrawn committed credit facilities, €795 billion of undrawn commercial paper programs and available cash. This solid liquidity position provides the Group with financial flexibility to support its operations, ongoing integration of IFF Pharma Solutions and future growth initiatives.

STRATEGY AND OUTLOOK

Roquette expects the current challenging market environment to continue. To sustain competitiveness, financial performance, and long-term value creation in these conditions, the company launched in January 2026 a comprehensive strategic company plan, by the name of ‘Shift & Lead’.

‘Shift & Lead’ builds on Roquette’s strong foundations as a diversified and resilient company, supported by family ownership and a long‑term vision, to strengthen operational excellence, innovation, financial discipline, and cash generation. This strategic plan aims to sustain growth and fully unlock the value of the company’s recent acquisitions, which enhance its leadership positions and open new pathways for profitable expansion.

Delivering this roadmap requires disciplined capital allocation and a robust financial structure. The Group remains committed to maintaining a strong investment-grade credit profile, ensuring continued access to financing to support investments in its people, industrial assets and innovation capabilities.

Supported by this solid plan and its diversified enlarged portfolio, Roquette enters 2026 with confidence in the resilience of its business model and the relevance of its strategic positioning to weather current challenges and emerge stronger.

The press release can be viewed on the Group’s website www.roquette.com.

Status of the accounts:
Audit procedures on the consolidated accounts are in progress.

About Roquette

Roquette is a global leader in sustainable plant-based solutions, driving innovation and strong partnerships that are shaping the future of nutrition, health, and bioindustry.

The company harnesses natural resources such as wheat, corn, seaweed, and cellulose to craft high-performance ingredients used in everyday foods, oral medications, advanced biopharmaceuticals, and a range of bio-based products.

A family-owned company with over 90 years of expertise and 11,000 employees, Roquette serves clients in over 150 countries and is committed to creating lasting value for customers, patients, consumers, and society.

Together, we turn the potential of nature into the essentials of life.

Discover more about Roquette here.

Press contacts:
Brunswick
Antoine Parison
+33 (0) 7 88 72 28 95
aparison@brunswickgroup.com

Roquette
Corporate Communications
Susannah Duquesne
Susannah.duquesne@roquette.com

Financial Communications
Cécile Masurel
cecile.masurel@roquette.com

DISCLAIMER – Certain statements contained in this press release may contain forecasts that specifically relate to future events, trends, plans or objectives. By nature, these forecasts involve identified and unidentified risks and uncertainties and may be affected by many factors likely to give rise to a significant discrepancy between the actual results and those indicated in these statements. The group does not undertake to publish an update or revision of these forecasts, or to communicate on new information, future events or any other special circumstance. The amounts presented in this presentation have been rounded to the nearest hundred/unit, which may result in slight discrepancies in totals. Thus, the financial data is provided for informational purposes only and may not exactly match the figures in the consolidated financial statements.

FINANCIAL INFORMATION – This press release and Roquette’s full regulated information are available on the Group’s website: Roquette website

GLOSSARY

To measure its performance, the Group uses certain financial indicators that are not defined by IFRS standards. These indicators are used in the operational monitoring of the Group’s activities and its financial communication (press releases, financial presentations, etc.).

APPENDIX 1 – INCOME STATEMENT

APPENDIX 2 – COMPREHENSIVE INCOME STATEMENT

APPENDIX 3 – BALANCE SHEET

APPENDIX 4 – CASH FLOW STATEMENT

APPENDIX 5 – GROSS DEBT TOWARDS FINANCIAL INSTITUTIONS

This aggregate excludes bank loans, loan issue fees, lease debts and accrued interest, and therefore reflects nominal amounts of indebtedness to financial institutions (banks and investors).

¹ Like-For-Like basis excludes exchange rates impact and perimeter variation.
² The definition of the alternative performance indicators is provided in the appendices of this press release.